The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma

American Journal of Physiology - Renal Physiology

Volumn 287, Issue 1 56-1, 2004, Pages

  Sufan, Roxana I ^a   Jewett, Michael A S ^b   Ohh, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

E3 ubiquitin ligase; Hypoxia inducible factor; Renal cell carcinoma

Indexed keywords

VON HIPPEL LINDAU PROTEIN;

CAUSE OF DEATH; CHROMOSOME 3P; CLEAR CELL CARCINOMA; COMPLEX FORMATION; EXON; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; GENE STRUCTURE; GENETIC LINKAGE; HUMAN; HYPOXIA; INHERITANCE; KIDNEY CANCER; KIDNEY CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN TARGETING; REVIEW; RNA TRANSLATION; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE; WILD TYPE;

EID: 2942689618     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00424.2003     Document Type: Review

References (89)

1. Bai C, Sen P, Hofmann K, Ma L, Goebl M, Harper JW, and Elledge SJ. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86: 263-274, 1996.
2. Bindra RS, Vasselli JR, Stearman R, Linehan WM, and Klausner RD. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 62: 3014-3019, 2002.
3. Blankenship C, Naglich J, Whaley J, Seizinger B, and Kley N. Alternate choice of initiation codon produces a biologically active product of the von Hippel-Lindau gene with tumor suppressor activity. Oncogene 18: 1529-1535, 1999.
4. Bunn HF and Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 76: 839-885, 1996.
5. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, Green J, Hsia YE, Lamiell J, Ming HW, Schmidt L, Kalman T, Kuzmin I, Stackhouse T, Latif F, Linehan WM, Lerman M, and Zbar B. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5: 66-75, 1995.
6. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, and Maher ER. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 10: 1029-1038, 2001.
7. Cockman M, Masson N, Mole D, Jaakkola P, Chang G, Clifford S, Maher E, Pugh C, Ratcliffe P, and Maxwell P. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741, 2000.
8. Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S, Jacobs SC, and Brown RS. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 301: 592-595, 1979.
9. Corless CL, Kibel A, Iliopoulos O, and Kaelin WGJ. Immunostaining of the von Hippel-Lindau gene oroduct (pVHL) in normal and neoplastic human tissues. Hum Pathol 28: 459-464, 1997.
10. Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Lerman MI, Zbar B, Affara NA, Ferguson-Smith MA, and Maher ER. Identification of intragenic mutations in the von Hippel-Lindau disease tumor suppressor gene and correlation with disease phenotype. Hum Mol Gen 3: 1303-1308, 1994.
11. Dames SA, Martinez-Yamout M, De Guzman RN, Dyson HJ, and Wright PE. Structural basis for Hif-1α/CBP recognition in the cellular hypoxic response. Proc Natl Acad Sci U SA 99: 5271-5276, 2002.
12. Dang C and Semenza G. Oncogenic alterations of metabolism. Trends Biochem Sci 24: 68-72, 1999.
13. 1- integrin fibrillar adhesions. Cancer Res 62: 2929-2936, 2002.
14. Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, Wagner G, and Eck MJ. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α. Proc Natl Acad Sci USA 99: 5367-5372, 2002.
15. Gill IS, Matin SF, Desai MM, Kaouk JH, Steinberg A, Mascha E, Thornton J, Sherief MH, Strzempkowski B, and Novick AC. Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients. J Urol 170: 64-68, 2003.
16. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, Lubensky I, Duan DR, Florence C, Pozzatti R, Walther MM, Bander NH, Grossman HB, Brauch H, Pomer S, Brooks JD, Isaacs WB, Lerman MI, Zbar B, and Linehan WM. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85-90, 1994.
17. Gnarra JR, Zhou S, Merrill MJ, Wagner J, Krumm A, Papavassiliou E, Oldfield EH, Klausner RD, and Linehan WM. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumor suppressor gene product. Proc Natl Acad Sci USA 93: 10589-10594, 1996.
18. Haase VH, Glickman JN, Socolovsky M, and Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA 98: 1583-1588, 2001.
19. Han KR, Bleumer I, Pantuck AJ, Kim HL, Dorey FJ, Janzen NK, Zisman A, Dinney CP, Wood CG, Swanson DA, Said JW, Figlin RA, Mulders PF, and Belldegrun AS. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol 170: 2221-2224, 2003.
20. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, and Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 5: 64-70, 2003.
21. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, and Kaelin WG Jr. Von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10: 1019-1027, 2001.
22. Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu YZ, Pray-Grant M, Perdew GH, and Bradfield CA. Characterization of a subset of the basic-helix-loop- helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J Biol Chem 272: 8581-8593, 1997.
23. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95: 7987-7992, 1998.
24. Iliopoulos O, Jiang C, Levy AP, Kaelin WG, and Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93: 10595-10599, 1996.
25. Iliopoulos O, Kibel A, Gray S, and Kaelin WG. Tumor suppression by the human von Hippel-Lindau hene product. Nat Med 1: 822-826, 1995.
26. Iliopoulos O, Ohh M, and Kaelin W. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 95: 11661-11666, 1998.
27. 2 sensing. Science 292: 464-468, 2001.
28. Ivanov S, Kuzmin I, Wei MH, Pack S, Geil L, Johnson B, Stanbridge E, and Lerman M. Down-regulation of transmembrance carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 95: 12596-12601, 1998.
29. 2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.
30. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, and Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 53: 5-26, 2003.
31. Kamura T, Sato S, Iwain K, Czyzyk-Krzeska M, Conaway RC, and Conaway JW. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau tumor suppressor complex. Proc Natl Acad Sci USA 97: 10430-10435, 2000.
32. Kessler P, Vasavada S, Rackley R, Stackhouse T, Duh F, Latif F, Lerman M, Zbar B, and Williams B. Expression of the von Hippel-Lindau tumor-suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Mol Med 1: 457-466, 1995.
33. Kim M, Katayose Y, Li Q, Rakkar A, Li Z, Hwang S, Katayose D, Trepel J, Cowan K, and Seth P. Recombinant adenovirus expressing Von Hippel-Lindau- mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1. Biochem Biophys Res Commun 253: 672-677, 1998.
34. Koochekpour S, Jeffers M, Wang P, Gong C, Taylor G, Roessler L, Stearman R, Vasselli J, Stetler-Stevenson W, Kaelin WJ, Linehan W, Klausner R, Gnarra J, and Vande Woude G. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 19: 5902-5912, 1999.
35. Kovacs G, Brusa P, and De Riese W. Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas. Int J Cancer 43: 422-427, 1989.
36. Kovacs G, Erlandsson R, Boldog F, Ingvarsson S, Muller-Brechlin R, Klein G, and Sumegi J. Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci USA 85: 1571-1575, 1988.
37. Krieg M, Marti H, and Plate KH. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 92: 3388-3393, 1998.
38. Kuznetsova AV, Meller J, Schnell PO, Nash JA, Ignacak ML, Sanchez Y, Conaway JW, Conaway RC, and Czyzyk-Krzeska MF. Von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc Natl Acad Sci USA 100: 2706-2711, 2003.
39. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, and Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16: 1466-1471, 2002.
40. Lando D, Peet DJ, Whelan DA, Gorman JJ, and Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295: 858-861, 2002.
41. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan DSR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Pasiler DL, Chumakov I, Cohen D, Chinault AC, Maher ER, Linehan WM, Zbar B, and Lerman MI. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317-1320, 1993.
42. Leung SK and Ohh M. Playing tag with HIF: the VHL story. J Biomed Biotechnol 2: 131-135, 2002.
43. Li Z, Na X, Wang D, Schoen SR, Messing EM, and Wu G. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem 277: 4656-4662, 2002.
44. Li Z, Wang D, Na X, Schoen SR, Messing EM, and Wu G. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1α transcriptional activity. EMBO J 22: 1857-1867, 2003.
45. Linehan WM, Walther MM, and Zbar B. The genetic basis of cancer of the kidney. J Urol 170: 2163-2172, 2003.
46. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, and Kaelin WG. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 18: 732-741, 1998.
47. Los M, Jansen GH, Kaelin WG, Lips CJM, Blijham GH, and Voest EE. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 75: 231-238, 1996.
48. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, and Zhuang Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 149: 2089-2094, 1996.
49. Maher E and Kaelin WG. Von Hippel-Lindau disease. Medicine 76: 381-391, 1997.
50. Mahon PC, Hirota K, and Semenza GL. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 2675-2686, 2001.
51. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, and Klausner RD. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1: 247-255, 2002.
52. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, and Hendrix MJ. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 14: 176-186, 1996.
53. Maxwell P, Weisner M, Chang GW, Clifford S, Vaux E, Pugh C, Maher E, and Ratcliffe P. The von Hippel-Lindau gene product is necessary for oxgyen-dependent proteolysis of hypoxia-inducible factor α subunits. Nature 399: 271-275, 1999.
54. Na X, Duan HO, Messing EM, Schoen SR, Ryan CK, di Sant'Agnese PA, Golemis EA, and Wu G. Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J 22: 4249-4259, 2003.
55. Ohh M and Kaelin WG Jr. VHL and kidney cancer. Methods Mol Biol 222: 167-183, 2003.
56. Ohh M, Kim WY, Moslehi JJ, Chen Y, Chau V, Read MA, and Kaelin WG. An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep 3: 177-182, 2002.
57. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Chau V, and Kaelin WG. Ubiquitination of HIF requires direct binding to the von Hippel-Lindau protein beta domain. Nat Cell Biol 2: 423-427, 2000.
58. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG, Iliopoulos O, and Kaelin WG. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1: 959-968, 1998.
59. Ohta T, Michel JJ, Schottelius AJ, and Xiaong Y. ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol Cell 3: 535-541, 1999.
60. Okuda H, Hirai S, Takaki Y, Kamada M, Baba M, Sakai N, Kishida T, Kaneko S, Yao M, Ohno S, and Shuin T. Direct interaction of the β-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem Biophys Res Commun 263: 491-497, 1999.
61. Pathak S, Strong LC, Ferrell RE, and Trindade A. Familial renal cell carcinoma with a 3;11 chromosome translocation limited to tumor cells. Science 217: 939-941, 1982.
62. Pause A, Lee S, Lonergan KM, and Klausner RD. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA 95: 993-998, 1998.
63. Pause A, Lee S, Worrell RA, Chen DYT, Burgess WH, Linehan WM, and Klausner RD. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 94: 2156-2161, 1997.
64. Rendon RA, Kachura JR, Sweet JM, Gertner MR, Sherar MD, Robinette M, Tsihlias J, Trachtenberg J, Sampson H, and Jewett MA. The uncertainty of radio frequency treatment of renal cell carcinoma: findings at immediate and delayed nephrectomy. J Urol 167: 1587-1592, 2002.
65. Richards F, Schofield P, Fleming S, and Maher E. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 5: 639-644, 1996.
66. Richards FM, Maher ER, Latif F, Phipps ME, Tory K, Lush M, Crossey PA, Oostra B, Gustavson KH, Green J, Turner G, Yates JRW, Lineham WH, Affara NA, Lerman M, Zbar B, and Ferguson-Smith MA. Detailed genetic mapping of the von Hippel-Lindau disease tumour supressor gene. J Med Genet 30: 104-107, 1993.
67. Schoenfeld A, Davidowitz EJ, and Burk RD. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 95: 8817-8822, 1998.
68. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, Haines J, Yuen JWM, Collins D, Majoor-Krakauer D, Bonner T, Mathew C, Rubenstein A, Halperin J, McConkie-Rosell A, Green JS, Trofatter JA, Ponder BA, Eierman L, Bowmer MI, Schimke R, Oostra B, Aronin N, Smith DI, Drabkin H, Waziri MH, Hobbs WJ, Martuza RL, Conneally PM, Hsia YE, and Gusella JF. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332: 268-269, 1988.
69. Semenza G. Perspectives on oxygen sensing. Cell 98: 281-284, 1999.
70. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551-578, 1999.
71. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, and Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 56: 2299-2301, 1996.
72. Skowyra D, Koepp DM, Kamura T, Conrad MN, Conaway RC, Conaway JW, Elledge SJ, and Harper JW. Reconstitution of G1 cyclin ubiquitination with complexes containing SCFGrr1 and Rbx1. Science 284: 662-665, 1999.
73. Sly WS and Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 64: 375-401, 1995.
74. Srinivas V, Zhang L, Zhu X, and Caro J. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor α (HIF-α) proteins. Biochem Biophys Res Commun 260: 557-561, 1999.
75. Stebbins CE, Kaelin WG, and Pavletich NP. Structure of the VHL-elongin C-elonginB complex: implications for VHL tumor suppressor function. Science 284: 455-461, 1999.
76. Stratmann R, Krieg M, Haas R, and Plate K. Putative control of angiogenesis in hemangioblastomas by the von Hippel-Lindau tumor suppressor gene. J Neuropath Exp Neurol 56: 1242-1252, 1997.
77. Tan P, Fuchs SY, Chen A, Wu K, Gomez C, Ronai Z, and Pan ZQ. Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of 1κBα. Mol Cell 3: 527-533, 1999.
78. Tanimoto K, Makino Y, Pereira T, and Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J 19: 4298-4309, 2000.
79. Van der Harst E, de Krijger R, Dinjens W, Weeks L, Bonjer H, Bruining H, Lamberts S, and Koper J. Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. Int J Cancer 77: 337-340, 1998.
80. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, and Jewett MA. The natural history of incidentally detected small renal masses. Cancer 100: 738-745, 2004.
81. Wenger R. Mammalian oxygen sensing, signalling and gene regulation. J Exp Biol 203: 1253-1263, 2000.
82. Wiener CM, Booth G, and Semenza GL. In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem Biophys Res Commun 225: 485-488, 1996.
83. Wizigmann-Voos S, Breier G, Risau W, and Plate K. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55: 1358-1364, 1995.
84. Yao M, Latif F, Orcutt M, Kuzmin I, Stackhouse T, Zhou F, Tory K, Duh F, Richards F, Maher E, LaForgia S, Huebner K, Le Paslier D, Linehan M, Lerman M, and Zbar B. Von Hippel-Lindau disease: identification of deletion mutations by pulsed field gel electrophoresis. Hum Genet 92: 605-614, 1993.
85. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, and Maher ER. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62: 3803-3811, 2002.
86. Zatyka M, Morrissey C, Kuzmin I, Lerman MI, Latif F, Richards FM, and Maher ER. Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter. J Med Genet 39: 463-472, 2002.
87. Zbar B, Brauch H, Talmadge C, and Linehan M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327: 721-724, 1987.
88. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, Crossey PA, Webster AR, Affara NA, Ferguson-Smith MA, Brauch H, Glavac D, Neumann HPH, Tisherman S, Mulvihill JJ, Gross D, Shuin T, Whaley J, Seizinger B, Kley N, Olschwang S, Boisson C, Richard S, Lips CHM, Linehan MW, and Lerman M. Germline mutations in the von Hippel-Lindau (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8: 348-357, 1996.
89. Zhu H and Bunn F. Oxygen sensing and signaling: impact on the regulation of physiologically important genes. Respir Physiol 115: 239-247, 1999.